WallStreetZenWallStreetZen

NASDAQ: APRE
Aprea Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for APRE

Based on 2 analysts offering 12 month price targets for Aprea Therapeutics Inc.
Min Forecast
$11.00+112.77%
Avg Forecast
$15.50+199.81%
Max Forecast
$20.00+286.85%

Should I buy or sell APRE stock?

Based on 2 analysts offering ratings for Aprea Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APRE stock forecasts and price targets.

APRE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-26

1 of 1

Forecast return on equity

Is APRE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is APRE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

APRE revenue forecast

What is APRE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$600.0k+2.88%
Avg 2 year Forecast
$600.0k+2.88%
Avg 3 year Forecast
$600.0k+2.88%
APRE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APRE revenue growth forecast

How is APRE forecast to perform vs Biotechnology companies and vs the US market?
Company
0.95%
Industry
37.5%
Market
10.08%
APRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APRE$5.17$15.50+199.81%Buy
IGC$0.44N/AN/A
PTN$1.73$70.00+3,946.24%Buy
ENLV$1.50$7.00+366.67%Buy
LEXX$2.20$12.00+445.45%Strong Buy

Aprea Therapeutics Stock Forecast FAQ

Is Aprea Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: APRE) stock is to Buy APRE stock.

Out of 2 analysts, 0 (0%) are recommending APRE as a Strong Buy, 2 (100%) are recommending APRE as a Buy, 0 (0%) are recommending APRE as a Hold, 0 (0%) are recommending APRE as a Sell, and 0 (0%) are recommending APRE as a Strong Sell.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.

What is APRE's revenue growth forecast for 2024-2026?

(NASDAQ: APRE) Aprea Therapeutics's forecast annual revenue growth rate of 0.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Aprea Therapeutics's revenue in 2024 is $583,231.On average, 1 Wall Street analysts forecast APRE's revenue for 2024 to be $3,258,129, with the lowest APRE revenue forecast at $3,258,129, and the highest APRE revenue forecast at $3,258,129. On average, 1 Wall Street analysts forecast APRE's revenue for 2025 to be $3,258,129, with the lowest APRE revenue forecast at $3,258,129, and the highest APRE revenue forecast at $3,258,129.

In 2026, APRE is forecast to generate $3,258,129 in revenue, with the lowest revenue forecast at $3,258,129 and the highest revenue forecast at $3,258,129.

What is APRE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APRE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is APRE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year APRE price target, the average APRE price target is $15.50, with the highest APRE stock price forecast at $20.00 and the lowest APRE stock price forecast at $11.00.

On average, Wall Street analysts predict that Aprea Therapeutics's share price could reach $15.50 by Mar 27, 2025. The average Aprea Therapeutics stock price prediction forecasts a potential upside of 199.81% from the current APRE share price of $5.17.

What is APRE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APRE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.